AstraZeneca PLC (AZN) Latest Company News

Sep 24, 2026, 06:07 UTC
EcoCeres announced a partnership with AstraZeneca to supply hydrotreated vegetable oil (HVO) renewable fuel for backup power generation at AstraZeneca's pharmaceutical manufacturing site in Wuxi, Jiangsu Province, China.
Source:
- aastocks.com
- aastocks.com
Sep 23, 2026, 16:01 UTC
The European Union approved AstraZeneca's Trixeo for the treatment of asthma, adding an indication supported by phase III data showing improved lung function.
Source:
- zacks.com
Sep 23, 2026, 12:10 UTC
Polaris Rx was selected as the exclusive U.S. distributor of AstraZeneca's FluMist Home at-home flu vaccine service for the 2026-2027 flu season, the second consecutive year it has held the role.
Source:
- businesswire.com
Sep 23, 2026, 08:14 UTC
AstraZeneca announced a new five-year phase of its Young Health Programme with UNICEF and 60 NGOs, aiming to reach 10 million more young people and train 800,000 youth advocates by 2030 with cumulative investment expected to exceed $100 million.
Sep 23, 2026, 07:57 UTC
The European Commission approved AstraZeneca's Trixeo Aerosphere for maintenance treatment of asthma in patients aged 12 and older whose condition is not adequately controlled by dual inhaled therapy.
Source:
- marketscreener.com
- rttnews.com
Sep 22, 2026, 21:59 UTC
An Integrated Genomic Sequencing Centre was inaugurated at the NATCO Cancer Centre at Government General Hospital in Guntur, established in collaboration with AstraZeneca and Strand Life Sciences.
Source:
- thehansindia.com
Sep 21, 2026, 18:31 UTC
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive recommendation for AstraZeneca's Klygefa for the treatment of AChR-positive generalised myasthenia gravis in the EU.
Source:
- zacks.com
Sep 18, 2026, 18:00 UTC
The FDA granted priority review to AstraZeneca's filing for efzimfotase alfa, a treatment for the rare bone disease hypophosphatasia (HPP).
Source:
- zacks.com
Sep 18, 2026, 10:02 UTC
AstraZeneca CEO Soriot bought ordinary shares of the company worth £7.26 million.
Source:
- finance.sina.cn
Sep 17, 2026, 13:30 UTC
The National Institute for Health and Care Excellence (NICE) issued a positive recommendation for reimbursement in England of AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) as monotherapy for adults with unresectable or metastatic HER2 Low breast cancer.
Source:
- rttnews.com
Sep 17, 2026, 07:15 UTC
Bavarian Nordic A/S appointed Tarja Stenvall as President and Chief Executive Officer effective October 15, 2026, succeeding Paul Chaplin.
Source:
Sep 17, 2026, 03:26 UTC
AstraZeneca announced an investment of nearly RMB 200 million to upgrade the new drug development and supply building at its Wuxi production and supply base for process development and production of an investigational cardiovascular drug and global supply after commercialization.
Source:
Sep 15, 2026, 11:34 UTC
AstraZeneca's Japan subsidiary invited three Japanese drug-discovery and medical-device startups, including Cuorips, to its global headquarters in Cambridge, UK, for discussions on overseas expansion as part of an Osaka Prefecture-backed startup support program.
Source:
- nikkei.com
Sep 15, 2026, 10:41 UTC
Zacks added Aptiv, AstraZeneca and Bank OZK to its Zacks Rank #5 (Strong Sell) list on September 15, 2026.
Source:
- zacks.com
Sep 14, 2026, 09:15 UTC
Eris Lifesciences elevated Sanjeev Mehra to Vice President – Human Resources & Organisational Development in April 2026.
Source:
- hrkatha.com
Sep 11, 2026, 03:55 UTC
In US after-hours trading on September 11, 2026, most pharmaceutical and biotech stocks rose, with Eli Lilly up 0.03%, Johnson & Johnson up 0.32%, Merck up 0.09%, Novartis up 0.14%, AstraZeneca up 0.38% and Novo Nordisk up 0.11%.
Source:
- m.21jingji.com
Sep 9, 2026, 00:20 UTC
On the fifth and final day of the 2026 national medical insurance drug list negotiations, price consultations for the commercial insurance innovative drug catalog began, with multiple pharmaceutical companies including AstraZeneca, Sanofi, and subsidiaries of Kechi Life and Hengrundasheng entering the venue.
Source:
Sep 8, 2026, 11:45 UTC
AstraZeneca announced that in the TITANIA study, Tozorakimab 300mg reduced the risk of moderate-to-severe exacerbations by 29% in the overall COPD patient population who are current or former smokers.
Source:
Sep 8, 2026, 06:20 UTC
China's Ministry of Commerce added 84 new key foreign-invested projects, including six landmark projects such as Fujian Benz Phase II and AstraZeneca's global strategic R&D center, with total investment of $19.46 billion.
Source:
Sep 1, 2026, 06:05 UTC
AstraZeneca completed its acquisition agreement for ZEGFROVY.
Source:
- finance.sina.cn
Aug 28, 2026, 09:23 UTC
AstraZeneca announced on Friday that its Phase 3 clinical trial for an experimental silencer drug in ATTR-CM patients failed to show additional benefit over existing stabilizer therapy, impacting its partnership with Ionis Pharmaceuticals and the broader market.
Source:
Aug 27, 2026, 06:00 UTC
Amgen and AstraZeneca announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE (tezepelumab-ekko) in patients with eosinophilic esophagitis, showing statistically significant and clinically meaningful improvements across co-primary and key secondary endpoints through week 52.
Source:

← PreviousPage 2Next →

AZN

EcoCeres announced a partnership with AstraZeneca to supply hydrotreated vegetable oil (HVO) renewable fuel for backup power generation at AstraZeneca's pharmaceutical manufacturing site in Wuxi, Jiangsu Province, China.

The European Union approved AstraZeneca's Trixeo for the treatment of asthma, adding an indication supported by phase III data showing improved lung function.

Polaris Rx was selected as the exclusive U.S. distributor of AstraZeneca's FluMist Home at-home flu vaccine service for the 2026-2027 flu season, the second consecutive year it has held the role.

AstraZeneca announced a new five-year phase of its Young Health Programme with UNICEF and 60 NGOs, aiming to reach 10 million more young people and train 800,000 youth advocates by 2030 with cumulative investment expected to exceed $100 million.

The European Commission approved AstraZeneca's Trixeo Aerosphere for maintenance treatment of asthma in patients aged 12 and older whose condition is not adequately controlled by dual inhaled therapy.

An Integrated Genomic Sequencing Centre was inaugurated at the NATCO Cancer Centre at Government General Hospital in Guntur, established in collaboration with AstraZeneca and Strand Life Sciences.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive recommendation for AstraZeneca's Klygefa for the treatment of AChR-positive generalised myasthenia gravis in the EU.

The FDA granted priority review to AstraZeneca's filing for efzimfotase alfa, a treatment for the rare bone disease hypophosphatasia (HPP).

AstraZeneca CEO Soriot bought ordinary shares of the company worth £7.26 million.

The National Institute for Health and Care Excellence (NICE) issued a positive recommendation for reimbursement in England of AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) as monotherapy for adults with unresectable or metastatic HER2 Low breast cancer.

Bavarian Nordic A/S appointed Tarja Stenvall as President and Chief Executive Officer effective October 15, 2026, succeeding Paul Chaplin.

AstraZeneca announced an investment of nearly RMB 200 million to upgrade the new drug development and supply building at its Wuxi production and supply base for process development and production of an investigational cardiovascular drug and global supply after commercialization.

AstraZeneca's Japan subsidiary invited three Japanese drug-discovery and medical-device startups, including Cuorips, to its global headquarters in Cambridge, UK, for discussions on overseas expansion as part of an Osaka Prefecture-backed startup support program.

Zacks added Aptiv, AstraZeneca and Bank OZK to its Zacks Rank #5 (Strong Sell) list on September 15, 2026.

Eris Lifesciences elevated Sanjeev Mehra to Vice President – Human Resources & Organisational Development in April 2026.

In US after-hours trading on September 11, 2026, most pharmaceutical and biotech stocks rose, with Eli Lilly up 0.03%, Johnson & Johnson up 0.32%, Merck up 0.09%, Novartis up 0.14%, AstraZeneca up 0.38% and Novo Nordisk up 0.11%.

AstraZeneca announced that in the TITANIA study, Tozorakimab 300mg reduced the risk of moderate-to-severe exacerbations by 29% in the overall COPD patient population who are current or former smokers.

China's Ministry of Commerce added 84 new key foreign-invested projects, including six landmark projects such as Fujian Benz Phase II and AstraZeneca's global strategic R&D center, with total investment of $19.46 billion.

AstraZeneca completed its acquisition agreement for ZEGFROVY.

AstraZeneca announced on Friday that its Phase 3 clinical trial for an experimental silencer drug in ATTR-CM patients failed to show additional benefit over existing stabilizer therapy, impacting its partnership with Ionis Pharmaceuticals and the broader market.

Amgen and AstraZeneca announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE (tezepelumab-ekko) in patients with eosinophilic esophagitis, showing statistically significant and clinically meaningful improvements across co-primary and key secondary endpoints through week 52.